Recently, an association between genetic deletion of cyclin-dependent kinase inhibitor 2A (CDKN2A/p16) and sensitivity to Chk1 inhibition was reported in HNSCC cell lines [38]. This evidence concerns the gene CDKN2A and head and neck squamous cell carcinoma.